Healthcare

The headline figure is described as contracted revenue, comprising both new sales and renewals. Alcidion said it expects the number to rise through new sales over the remaining eight months of the financial year, though such sales are not guaranteed.

Saluda develops neuromodulation treatments for chronic neurological conditions and is best known for spinal cord stimulation (SCS), a therapy for chronic pain. In the quarter, US revenue reached US$17.4m, a rise of 34 per cent on the prior corresponding period, while international revenue was …

Group revenue for the nine months to 30 September 2026 was A$25.9m, up 13.7 per cent from A$22.8m a year earlier. The group gross margin was 56.3 per cent, up from 53.5 per cent, per its first-half report. In the United States, third-quarter revenue …

The announcement describes the Galileo cassette as the platform into which the new test would be built, so the project combines Innovation Scientific's strip chemistry with Atomo's existing device design.

BlinkLab said the FDA clearance threshold for Dx1 is sensitivity and specificity above 65%. An earlier US pilot study in 485 children reported 84% sensitivity and 85% specificity. The company also plans to pursue CE/MDR clearance in Europe. It said the University of Pennsylvania …

Bubs said potential private label participation in the US market is subject to further regulatory, technical and commercial milestones, so the authorisation does not by itself represent a contract or revenue. The company said its products are now in more than 12,000 US stores …

Cambium finished the quarter to 30 September with A$1.194 million of cash, compared with A$1.104 million at 30 June. Net operating outflow was A$0.735 million, of which research and development accounted for A$0.506 million. Customer receipts were A$0.146 million, which the company attributes to …